Do analysts rate PETV or HSCS?

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PETV or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. HeartSciences' return on equity of -358.60% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% HeartSciences N/A -358.60% -144.82%

Is HSCS or LFWD more profitable?

HeartSciences has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. Lifeward's return on equity of -255.60% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% Lifeward -141.28% -255.60% -88.28%

Do analysts recommend ZJYL or HSCS?

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, ZJYL or HSCS?

Jin Medical International has higher revenue and earnings than HeartSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jin Medical International $20.69M 12.81 $1.19M N/A N/A HeartSciences N/A N/A -$9.14M -$3.94 N/A

Is ZJYL or HSCS more profitable?

Jin Medical International's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Jin Medical International N/A N/A N/A HeartSciences N/A -358.60% -144.82%

Is HSCS or ADGM more profitable?

HeartSciences' return on equity of -358.60% beat Adagio Medical's return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% Adagio Medical N/A -661.85% -73.35%

HeartSciences (HSCS) Competitors

$2.06 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.07 +0.01 (+0.49%)

As of 08/14/2026 07:55 PM Eastern

Compare

HSCS vs. PETV, CTSO, LFWD, ZJYL, and ADGM

Should you buy HeartSciences stock or one of its competitors? HeartSciences's main competitors and comparable companies include PetVivo (PETV), Cytosorbents (CTSO), Lifeward (LFWD), Jin Medical International (ZJYL), and Adagio Medical (ADGM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartSciences compare to PetVivo?

PetVivo (NASDAQ:PETV) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

HeartSciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. HeartSciences' return on equity of -358.60% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
HeartSciences	N/A	-358.60%	-144.82%

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, PetVivo had 2 more articles in the media than HeartSciences. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.89 beat PetVivo's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
PetVivo	Neutral
HeartSciences	Very Positive

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 10.8% of PetVivo shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PetVivo has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

HeartSciences has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	24.67	-$10.95M	-$0.34	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

Summary

HeartSciences beats PetVivo on 10 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

In the previous week, Cytosorbents had 8 more articles in the media than HeartSciences. MarketBeat recorded 9 mentions for Cytosorbents and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.89 beat Cytosorbents' score of -0.54 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytosorbents	Negative
HeartSciences	Very Positive

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HeartSciences has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. HeartSciences' return on equity of -358.60% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
HeartSciences	N/A	-358.60%	-144.82%

Cytosorbents has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Cytosorbents currently has a consensus target price of $5.38, indicating a potential upside of 1,244.09%. HeartSciences has a consensus target price of $8.00, indicating a potential upside of 288.35%. Given Cytosorbents' higher possible upside, equities analysts clearly believe Cytosorbents is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytosorbents has higher revenue and earnings than HeartSciences. Cytosorbents is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.68	-$8.20M	-$0.29	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

Summary

Cytosorbents beats HeartSciences on 8 of the 13 factors compared between the two stocks.

How does HeartSciences compare to Lifeward?

HeartSciences (NASDAQ:HSCS) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Lifeward had 4 more articles in the media than HeartSciences. MarketBeat recorded 5 mentions for Lifeward and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.89 beat Lifeward's score of 0.30 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Very Positive
Lifeward	Neutral

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by company insiders. Comparatively, 1.5% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HeartSciences has higher earnings, but lower revenue than Lifeward. HeartSciences is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A
Lifeward	$22.03M	0.96	-$19.91M	-$19.66	N/A

HeartSciences currently has a consensus target price of $8.00, indicating a potential upside of 288.35%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 34.23%. Given HeartSciences' higher possible upside, equities analysts clearly believe HeartSciences is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifeward	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. Lifeward's return on equity of -255.60% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Lifeward	-141.28%	-255.60%	-88.28%

HeartSciences has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

HeartSciences beats Lifeward on 7 of the 13 factors compared between the two stocks.

How does HeartSciences compare to Jin Medical International?

Jin Medical International (NASDAQ:ZJYL) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Jin Medical International has a beta of 7.33, indicating that its stock price is 633% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Jin Medical International has higher revenue and earnings than HeartSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jin Medical International	$20.69M	12.81	$1.19M	N/A	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

In the previous week, Jin Medical International had 2 more articles in the media than HeartSciences. MarketBeat recorded 3 mentions for Jin Medical International and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.89 beat Jin Medical International's score of 1.12 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Jin Medical International	Positive
HeartSciences	Very Positive

17.2% of HeartSciences shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Jin Medical International's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jin Medical International	N/A	N/A	N/A
HeartSciences	N/A	-358.60%	-144.82%

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Jin Medical International and HeartSciences tied by winning 6 of the 12 factors compared between the two stocks.

How does HeartSciences compare to Adagio Medical?

HeartSciences (NASDAQ:HSCS) and Adagio Medical (NASDAQ:ADGM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

HeartSciences has higher earnings, but lower revenue than Adagio Medical. HeartSciences is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A
Adagio Medical	$600K	25.62	-$25.08M	-$1.48	N/A

HeartSciences currently has a consensus target price of $8.00, indicating a potential upside of 288.35%. Adagio Medical has a consensus target price of $3.50, indicating a potential upside of 405.63%. Given Adagio Medical's stronger consensus rating and higher probable upside, analysts clearly believe Adagio Medical is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

HeartSciences' return on equity of -358.60% beat Adagio Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Adagio Medical	N/A	-661.85%	-73.35%

In the previous week, Adagio Medical had 3 more articles in the media than HeartSciences. MarketBeat recorded 4 mentions for Adagio Medical and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.89 beat Adagio Medical's score of -0.28 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Very Positive
Adagio Medical	Neutral

HeartSciences has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Adagio Medical has a beta of -0.15, indicating that its stock price is 115% less volatile than the broader market.

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 48.1% of Adagio Medical shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by company insiders. Comparatively, 7.8% of Adagio Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Adagio Medical beats HeartSciences on 10 of the 14 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.03M	$5.83B	$6.99B	$13.04B
Dividend Yield	N/A	1.75%	2.56%	10.42%
P/E Ratio	-0.52	26.60	271.55	25.35
Price / Sales	N/A	40.53	603.87	97.86
Price / Cash	N/A	33.83	28.87	38.43
Price / Book	29.43	6.10	11.24	6.52
Net Income	-$9.14M	$148.46M	$3.45B	$346.81M
7 Day Performance	-0.48%	1.12%	0.96%	1.26%
1 Month Performance	-23.42%	4.76%	2.31%	2.56%
1 Year Performance	-39.05%	9.14%	62.37%	20.83%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	2.8579 of 5 stars	$2.06 flat	$8.00 +288.3%	-39.1%	$8.03M	N/A	N/A	10	Positive News
PETV PetVivo	N/A	$0.69 -4.5%	N/A	-16.2%	$26.19M	$1.05M	N/A	20	Gap Up
CTSO Cytosorbents	1.7737 of 5 stars	$0.37 +2.8%	$5.38 +1,352.7%	-65.5%	$22.62M	$37.06M	N/A	220	Gap Down
LFWD Lifeward	2.2164 of 5 stars	$7.75 +2.4%	$10.00 +29.0%	-1.9%	$21.40M	$22.03M	N/A	60	Earnings Report Gap Up
ZJYL Jin Medical International	1.3237 of 5 stars	$3.49 +17.1%	N/A	-72.4%	$20.35M	$20.69M	N/A	245	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. PETV, CTSO, LFWD, ZJYL, and ADGM

How does HeartSciences compare to PetVivo?

Summary

How does HeartSciences compare to Cytosorbents?

Summary

How does HeartSciences compare to Lifeward?

Summary

How does HeartSciences compare to Jin Medical International?

Summary

How does HeartSciences compare to Adagio Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. PETV, CTSO, LFWD, ZJYL, and ADGM

How does HeartSciences compare to PetVivo?

Is PETV or HSCS more profitable?

Do analysts rate PETV or HSCS?

Does the media refer more to PETV or HSCS?

Do insiders and institutionals believe in PETV or HSCS?

Which has more volatility and risk, PETV or HSCS?

Which has higher valuation & earnings, PETV or HSCS?

Summary

How does HeartSciences compare to Cytosorbents?

Does the media favor CTSO or HSCS?

Do insiders and institutionals have more ownership in CTSO or HSCS?

Is CTSO or HSCS more profitable?

Which has more risk & volatility, CTSO or HSCS?

Do analysts rate CTSO or HSCS?

Which has higher valuation and earnings, CTSO or HSCS?

Summary

How does HeartSciences compare to Lifeward?

Does the media prefer HSCS or LFWD?

Do institutionals & insiders have more ownership in HSCS or LFWD?

Which has preferable earnings and valuation, HSCS or LFWD?

Do analysts recommend HSCS or LFWD?

Is HSCS or LFWD more profitable?

Which has more volatility & risk, HSCS or LFWD?

Summary

How does HeartSciences compare to Jin Medical International?

Which has more risk and volatility, ZJYL or HSCS?

Which has preferable earnings and valuation, ZJYL or HSCS?

Does the media refer more to ZJYL or HSCS?

Do institutionals and insiders believe in ZJYL or HSCS?

Is ZJYL or HSCS more profitable?

Do analysts recommend ZJYL or HSCS?

Summary

How does HeartSciences compare to Adagio Medical?

Which has better earnings and valuation, HSCS or ADGM?

Do analysts rate HSCS or ADGM?

Is HSCS or ADGM more profitable?

Does the media prefer HSCS or ADGM?

Which has more risk and volatility, HSCS or ADGM?

Do institutionals & insiders believe in HSCS or ADGM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools